View in EDS HTML Full Text PDF Full Text

Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)

Saved in:

Bibliographic Details
Title:	Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
Authors:	Iwuji, Collins^1,2 (AUTHOR) c.iwuji@bsms.ac.uk, Waters, Laura³ (AUTHOR), Milinkovic, Ana⁴ (AUTHOR), Orkin, Chloe^5,6 (AUTHOR), Fox, Julie⁷ (AUTHOR), Post, Frank⁸ (AUTHOR), Perry, Nicky⁹ (AUTHOR), Bruce, Chloe¹⁰ (AUTHOR), Dailey, Natalie¹⁰ (AUTHOR), To, Ye¹⁰ (AUTHOR), Bremner, Stephen^10,11 (AUTHOR), Churchill, Duncan⁹ (AUTHOR), Geretti, Anna Maria^12,13,14 (AUTHOR)
Source:	Virology Journal. 2/10/2025, Vol. 22 Issue 1, p1-11. 11p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Be the first to leave a comment!